Sun Pharma's Q2 profit drops 36 pc to Rs 1,989 crore on one-time loss

IANS | October 30, 2026 3:22 PM

Mumbai, Oct 30 (IANS) Sun Pharmaceutical Industries Limited on Friday reported a 36.2 per cent year-on-year (YoY) decline in consolidated net profit to Rs 1,988.53 crore for the quarter ended September 2026 (Q2 FY27), impacted by a one-time loss of Rs 1,269 crore.

Kerala Nipah drug row: Minister suspects clinical trial medicine was also supplied during Vijayan regime

IANS | October 30, 2026 2:37 PM

Kozhikode, Oct 30 (IANS) Kerala Health Minister, K. Muraleedharan, on Friday raised fresh questions over the medicines supplied to Nipah patients in the state during former Chief Minister Pinarayi Vijayan's regime, saying there were doubts whether a drug meant for clinical trials had also been administered to patients and that some medicines supplied lacked manufacturing dates.

‘No recognised medical degree’: Nine fake doctors held in Gujarat

IANS | October 29, 2026 10:09 PM

Surat, Oct 29 (IANS) As many as nine fake doctors were apprehended during simultaneous raids on clinics in the Dindoli area of Surat on Thursday, with the police and health department seizing medicines, injections, syrups and medical equipment worth around Rs 95,000, officials said on Thursday.

Expired Remdesivir in Kerala given to Nipah patients, govt orders probe

IANS | October 29, 2026 2:56 PM

Thiruvananthapuram, Oct 29 (IANS) Remdesivir that expired in May 2023 was administered to patients, including those treated for Nipah infection, at hospitals in Kerala in subsequent years, Health Minister K. Muraleedharan told the Assembly on Thursday, ordering an investigation into whether the use of the expired drug contributed to patient deaths.

Cipla Q2 profit falls 35 pc as North America weakness hits margins

IANS | October 27, 2026 2:18 PM

Mumbai, Oct 27 (IANS) Pharmaceutical major Cipla on Tuesday reported a 35 per cent year-on-year (YoY) decline in its consolidated net profit for the second quarter of FY27, as weaker sales in North America and a sharp contraction in operating margins weighed on its performance.